The National Cancer Institute (NCI) has awarded a $400,000 Project Grant under the Cancer Treatment Research (CFDA 93.395) program to Kure Ai Inc. to develop a novel pan-cancer CAR-T therapy targeting the MR1 protein for the treatment of acute myeloid leukemia (AML) and glioblastoma. The project aims to validate the cell surface expression of MR1 in these cancer types, conduct mouse efficacy studies, and assess the safety profile of the MR1 CAR-T product. This work is expected to lead to the development of an improved CAR-T cell therapy that can potentially benefit patients with these aggressive and difficult-to-treat malignancies. The project period runs from September 16, 2024 to August 31, 2025.
Generated 1/28/25, 10:24 AM